Corcept Therapeutics Incorporated (FRA:HTD)

Corcept Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	106.11	141.21	106.14	101.42	112.51	106.01
Depreciation & Amortization	1.87	1.34	2.36	3.45	3.48	2.24
Loss (Gain) From Sale of Investments	-6.2	-10.94	-9.13	1.38	-	-
Stock-Based Compensation	80.53	61.35	48.94	42.44	42.93	33.54
Other Operating Activities	-26.21	-40.19	-29.49	-33.91	9.44	15.54
Change in Accounts Receivable	-9.91	-12.85	-10.07	-3.43	-1.43	-6.27
Change in Inventory	-8.04	0.31	1.27	1.2	3.44	-3.51
Change in Accounts Payable	15.74	-2.25	5.78	4.76	-3.6	3.16
Change in Income Taxes	1.29	3.78	1.21	8.69	0.01	0.01
Change in Other Net Operating Assets	8.22	56.32	10.03	-5.67	1.1	1.25
Operating Cash Flow	163.38	198.07	127.04	120.32	167.89	151.97
Operating Cash Flow Growth	13.36%	55.91%	5.58%	-28.33%	10.48%	11.65%
Capital Expenditures	-0.28	-2.17	-0.14	-0.41	-0.47	-1.24
Investment in Securities	17.52	-175.43	91.05	-113.91	136.6	-118.03
Investing Cash Flow	17.24	-177.6	90.91	-114.33	136.13	-119.26
Issuance of Common Stock	22.59	9.62	5.81	4.38	16.23	23.23
Repurchase of Common Stock	-216.3	-37.97	-154.53	-21.67	-318.82	-11.01
Financing Cash Flow	-193.71	-28.35	-148.72	-17.28	-302.59	12.21
Net Cash Flow	-12.15	-7.89	69.22	-11.29	1.43	44.92
Free Cash Flow	163.1	195.9	126.9	119.91	167.42	150.73
Free Cash Flow Growth	14.80%	54.37%	5.83%	-28.38%	11.07%	11.63%
Free Cash Flow Margin	22.00%	29.02%	26.31%	29.84%	45.75%	42.59%
Free Cash Flow Per Share	1.36	1.73	1.14	1.03	1.33	1.21
Cash Income Tax Paid	60.27	60.27	47.6	39.75	9.1	10.86
Levered Free Cash Flow	135.72	183.85	128.39	115.55	120.18	116.42
Unlevered Free Cash Flow	135.72	183.85	128.39	115.55	120.18	116.42
Change in Working Capital	7.29	45.3	8.22	5.54	-0.47	-5.36

Source: S&P Global Market Intelligence. Standard template. Financial Sources.